AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
CTGF ELISA Kit, Recombinant, Antibody
Connective Tissue Growth Factor (CTGF)/CCN2 ELISA Kit

CTGF plays a role in severe hypertrophic cardiomyopathy and heart failure

  • Insulin-like growth factor-binding protein 8 (IGFBP-8)
  • Involved in angiogenesis, cell adhesion, cell migration, and ossification

Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.

Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction

IMS: Myocardial CCN2/CTGF is induced in heart failure of various etiologies. However, its role in the pathophysiology of left ventricular (LV)remodeling after myocardial infarction (MI) remains unresolved. The current study explores the role of CTGF in infarct healing and LV remodeling in an animal model and in patients admitted for acute ST-elevation MI.
METHODS AND RESULTS: Transgenic mice with cardiac-restricted overexpression of CTGF (Tg-CTGF) and non-transgenic littermate controls (NLC) were subjected to permanent ligation of the left anterior descending coronary artery. Despite similar infarct size (area of infarction relative to area at risk) 24 hours after ligation of the coronary artery in Tg-CTGF and NLC mice, Tg-CTGF mice disclosed smaller area of scar tissue, smaller increase of cardiac hypertrophy, and less LV dilatation and deterioration of LV function 4 weeks after MI. Tg-CTGF mice also revealed substantially reduced mortality after MI. Remote/peri-infarct tissue of Tg-CTGF mice contained reduced numbers of leucocytes, macrophages, and cells undergoing apoptosis as compared with NLC mice. In a cohort of patients with acute ST-elevation MI (n = 42) admitted to hospital for percutaneous coronary intervention (PCI) serum-CTGF levels (s-CTGF) were monitored and related to infarct size and LV function assessed by cardiac MRI. Increase in s-CTGF levels after MI was associated with reduced infarct size and improved LV ejection fraction one year after MI, as well as attenuated levels of CRP and GDF-15.
CONCLUSION: Increased myocardial CTGF activities after MI are associated with attenuation of LV remodeling and improved LV function mediated by attenuation of inflammatory responses and inhibition of apoptosis.
Gravning J, et al. PLoS One. 2012;7(12):e52120. doi: 10.1371/journal.pone.0052120. Epub 2012 Dec 20.

CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure

Hypertrophic cardiomyopathy (HCM) is the most common inherited primary myocardial disorder. HCM is characterized by interstitial fibrosis and excessive accumulation of extracellular matrix (ECM) proteins. Fibrosis in HCM has been associated with impaired cardiac function and heart failure, and has been considered a key substrate for ventricular arrhythmias and sudden death. The molecular triggers underpinning ECM production are not well established. We have previously developed a double-mutant mouse model of HCM that recapitulates the phenotype seen in humans with multiple mutations, including earlier onset of the disease, progression to a dilated phenotype, severe heart failure and premature mortality. The present study investigated the expression of ECM-encoding genes in severe HCM and heart failure. Significant upregulation of structural Fn1, regulatory Mmp14, Timp1, Serpin3A, SerpinE1, SerpineE2, Tgfβ1, and Tgfβ2; and matricellular Ccn2, Postn, Spp1, Thbs1, Thbs4, and Tnc was evident from the early, pre-phenotype stage. Non-myocytes expressed ECM genes at higher levels than cardiomyocytes in normal and diseased hearts. Synchronous increase of secreted CCN2 and TIMP1 plasma levels and decrease of MMP3 levels were observed in end-stage disease. CCN2 protein expression was increased from early disease in double-mutant hearts and played an important role in ECM responses. It was a powerful modulator of ECM regulatory (Timp1 and SerpinE1) and matricellular protein-encoding (Spp1, Thbs1, Thbs4 and Tnc) gene expression in cardiomyocytes when added exogenously in vitro. Modulation of CCN2 (CTGF, connective tissue growth factor) and associated early ECM changes may represent a new therapeutic target in the treatment and prevention of heart failure in HCM.
Tsoutsman T, et al. J Mol Cell Cardiol. 2013 Jun 10. pii: S0022-2828(13)00197-1. doi: 10.1016/j.yjmcc.2013.05.019. [Epub ahead of print]

Connective tissue growth factor is a new ligand of epidermal growth factor receptor

Chronic kidney disease is reaching epidemic proportions worldwide and there is no effective treatment. Connective tissue growth factor (CCN2) has been suggested as a risk biomarker and a potential therapeutic target for renal diseases, but its specific receptor has not been identified. Epidermal growth factor receptor (EGFR) participates in kidney damage, but whether CCN2 activates the EGFR pathway is unknown. Here, we show that CCN2is a novel EGFR ligand. CCN2 binding to EGFR extracellular domain was demonstrated by surface plasmon resonance. CCN2 contains four distinct structural modules. The carboxyl-terminal module (CCN2(IV)) showed a clear interaction with soluble EGFR, suggesting that EGFR binding site is located in this module. Injection of CCN2(IV) in mice increased EGFR phosphorylation in the kidney, mainly in tubular epithelial cells. EGFR kinase inhibition decreased CCN2(IV)-induced renal changes (ERK activation and inflammation). Studies in cultured tubular epithelial cells showed thatCCN2(IV) binds to EGFR leading to ERK activation and proinflammatory factors overexpression. CCN2 interacts with the neurotrophin receptor TrkA, and EGFR/TrkA receptor crosstalk was found in response to CCN2(IV) stimulation. Moreover, endogenous CCN2 blockade inhibited TGF-β-induced EGFR activation. These findings indicate that CCN2 is a novel EGFR ligand that contributes to renal damage through EGFR signalling.
Rayego-Mateos S, et al. J Mol Cell Biol. 2013 Aug 8. [Epub ahead of print]
 
human CTGF ELISA Kit SK00726-06 Human CTGF ELISA Kit
Code No.: SK00726-06
Size: 96 T
Price: $420.00 USD
Standard Range:62.5-4000 pg/ml
Sensitivity:30 pg/ml
Sample Type: cell culture, serum, EDTA plasma
Sample requres: 100uL per well
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
  Human CTGF ELISA Kit
Code No.: SK00726-01
Size:192 T
Price: $720.00 USD
Standard Range:250-8000 pg/ml
Sensitivity:100-125 pg/ml
Sample Type: cell culture, serum, EDTA plasma
Sample requres: 100uL per well
IntraCV: 6-8%
InterCV: 10-12%
Protocol: PDF
anti human CGTF antibody enables to stain mouse lung tissues Anti Human CTGF IgG
Code No.: A00726-01-100
Size: 100 ug
Price: $22.00 USD
Immunogen: human CTGF rec.
Host: Rabbit
Ab Type:IgG
Application E, IHC, WB
Working Conc.: 2 ug/ml
Carry: free
Data Sheet: PDF
anti human CTGF antibody stains rat lung tissues Anti Human CTGF IgG
Code No.: A00726-01-100
Size: 100 ug
Price: $22.00 USD
Immunogen: human CTGF rec.
Host: Rabbit
Ab Type:IgG
Application E, IHC, WB
Working Conc.: 2 ug/ml
Carry: free
Data Sheet: PDF

human CTGF recombinant

Human CTGF,Recombinant
Code No.: 00726-01-100
Size: 100 ug
Price: $360.00 USD
Protein ID:P29279
Gene ID: 1490
MW:34 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 90%
Data Sheet: PDF
  Goat Anti Human CTGF IgG
Code No.: A00726-06-100
Size: 100 ug
Price: $22.00 USD
Immunogen: human CTGF rec.
Host: Goat
Ab Type:IgG
Application E, IHC, WB
Working Conc.: 2 ug/ml
Carry: free
Data Sheet: PDF

 

Name
Code No.
Size
Price ($)
CTGF (Human) ELISA Kit (96T)
96 T
420.00
CTGF (Human) ELISA Kit (192T)
192 T
720.00
CTGF (Human) Rec.
100 ug
360.00
CTGF (Human) Rec.
00726-01-1000
1000 ug
3200.00
Anti CTGF (Human) IgG
100 ug
220.00
Anti CTGF (Human) IgG , Biotinylated
50 ug
260.00
Goat Anti CTGF (Human) IgG
100 ug
290.00
Goat Anti CTGF (Human) IgG
200 ug
420.00
Goat Anti CTGF (Human) IgG, biotinylated
50 ug
310.00
Goat Anti CTGF (Human) IgG, biotinylated
100 ug
500.00
Goat Anti CTGF (Human) IgG, Cy3 conjugated
A00726-06-50C3
50 ug
460.00
Goat Anti CTGF (Human) IgG, FAM conjugated
A00726-06-50FAM
50 ug
390.00